OTC : SNPHY

Santen Pharmaceutical Co., Ltd.

$12.22 USD

$0.57 (4.94%)

Volume
202
Average Volume
3.15K
Market Capitalization
$3.93B
P/E Ratio
16.27
Dividend Yield
2.05%
Price Target
Year High
$13.93
Year Low
$9.22
Day High
—
Day Low
—
Payout Ratio
$0.34
Current Ratio
$2.60
Company Overview

OTC

Takeshi Ito

Drug Manufacturers - General

Healthcare

SNPHY

3968

JP

USD

https://www.santen.com

81 6 7664 8621

80287P100

N/A

Liquidity Metrics

0.12

2.60

1.87

0.92

0.34

Sales & Valuation

$309.21B

2.05

2.03

16.28

112.78

Profitability

$121.43

$39.62B

12.81%

16.27%

13.15%

8.83%

P/E Metrics

16.27

1.68

1.68

Analyst Price Target & Rating

Buy

4/5

0 Analysts

%

Financial Health Scores

4.91

7/9

$141.5B

$424.87B

$127.57B

$46.7B

Key Metrics (TTM)

$550.77B

1.89

8.12

2.60

13.15%

10.57%

6.19%

6.14%

$1537.30

172 days

Company Executives
Name Title
Chris Hoffman Group Manager of Corporate Communications Group
Giyomu Sakuma Manager of Investor Relations
Takeshi Matsugi Head of R&D Strategic Operations
Tomohisa Watanabe Corporate Officers & Global Head of Corporate Strategy
Tomoyuki Yoshida Head of Asia Business & Corporate Officer
Marianthi Psacha Corporate Officer, Head of EMEA Business and International Pricing Market Access & Public Affairs
Rie Nakajima COO & Director
Yoshinori Watanabe Corporate Officer and Head of Sales & Marketing Division – OTC products
Kazuo Koshiji Chief Financial Officer & Corporate Officer
Kenji Morishima Corporate Officer & Head of China Product Development Department
Takeshi Ito President, Chief Executive Officer & Representative Director
Mika Masunari Corporate Officer, General Counsel, Chief Risk Officer & Chief Compliance Officer
Shinichi Teramachi Corporation Officer, Head of Sales and Head of Japan Sales & Marketing
Takahiro Morita Global Head of Core Principle & Sustainability and Corporate Officer
Yoko Saiki Corporate Officer & Chief Human Resources Officer
Daisuke Nakata Chief Digital & Information Officer
Kaori Itagaki General Manager of Investor Relations Group
Poll Results

No votes yet today — be the first to share your view!

About Santen Pharmaceutical Co., Ltd. (OTC:SNPHY) Stock

Santen Pharmaceutical Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and distribution of pharmaceuticals and medical devices, with operations spanning Japan and international markets. The company maintains a significant pipeline and array of products focused on ophthalmic conditions. For glaucoma and ocular hypertension, their drug candidates encompass DE-111, currently undergoing Phase III clinical evaluation; DE-117, which is available in Japan; DE-126, now in Phase IIb trials; DE-128, being developed for European markets and also in Phase II/III trials within the United States; and DE-130A, another compound advancing through Phase III clinical trials. Santen's development efforts also extend to treatments for other eye ailments: DE-114A for aller ... gic conjunctivitis, DE-076C to address vernal keratoconjunctivitis, and DE-109, a therapy for uveitis that is in Phase III trials. Furthermore, their initiatives against myopia include DE-127, which is simultaneously in Phase II/III clinical trials in Japan and Phase III across Asia, alongside STN1013400, currently in its initial Phase I clinical trials for the same condition. They also offer DE-089C, a treatment for dry eye that has successfully completed its Phase III clinical trials. Beyond prescription medications, Santen also supplies a selection of over-the-counter pharmaceutical products. The corporation, founded in Osaka, Japan, in 1890, was initially known as Santendo Pharmaceutical Co., Ltd. before formally adopting its current name, Santen Pharmaceutical Co., Ltd., in 1958.

Frequently Asked Questions

What is the current Santen Pharmaceutical Co., Ltd. (SNPHY) stock price?

Santen Pharmaceutical Co., Ltd.(OTC:SNPHY) stock price is $12.22 in the last trading session. During the trading session, SNPHY stock reached the peak price of $13.93 while $9.22 was the lowest point it dropped to. The percentage change in SNPHY stock occurred in the recent session was 4.94% while the dollar amount for the price change in SNPHY stock was $0.57.

SNPHY's industry and sector of operation?

The OTC listed SNPHY is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of SNPHY?

Chris Hoffman | Group Manager of Corporate Communications Group
Giyomu Sakuma | Manager of Investor Relations
Takeshi Matsugi | Head of R&D Strategic Operations
Tomohisa Watanabe | Corporate Officers & Global Head of Corporate Strategy
Tomoyuki Yoshida | Head of Asia Business & Corporate Officer

How many employees does SNPHY have?

Number of SNPHY employees currently stands at 3968. SNPHY operates from Grand Front Osaka Tower A, Osaka, OS 530-8552, JP.

Link for SNPHY official website?

Official Website of SNPHY is: https://www.santen.com

How do I contact SNPHY?

SNPHY could be contacted at phone #81 6 7664 8621 and can also be accessed through its website. SNPHY operates from Grand Front Osaka Tower A, Osaka, OS 530-8552, JP.

How many shares of SNPHY are traded daily?

The average number of SNPHY shares traded daily for last 3 months was 3.15K.

What is the market cap of SNPHY currently?

The market value of SNPHY currently stands at $3.93B with its latest stock price at $12.22